1620 Investment Advisors’s AbbVie ABBV Stock Holding History

1620 Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Sell	7,146 -387	-5%	-$83.3K	1.11%	16
2026 Q1	$1.64M	Buy	7,533 +16	+0.2%	+$3.55K	1.11%	16
2025 Q4	$1.72M	Sell	7,517 -13	-0.2%	-$2.96K	1.14%	18
2025 Q3	$1.74M	Sell	7,530 -123	-2%	-$25K	1.18%	17
2025 Q2	$1.42M	Buy	7,653 +163	+2%	+$30.3K	1.01%	20
2025 Q1	$1.57M	Buy	7,490 +59	+0.8%	+$11.5K	1.2%	17
2024 Q4	$1.32M	Sell	7,431 -133	-2%	-$24.5K	1%	19
2024 Q3	$1.49M	Sell	7,564 -791	-9%	-$148K	1.08%	16
2024 Q2	$1.43M	Buy	8,355 +809	+11%	+$134K	1.1%	16
2024 Q1	$1.37M	Buy	7,546 +123	+2%	+$21.2K	1.38%	16
2023 Q4	$1.15M	Sell	7,423 -285	-4%	-$41.5K	1.26%	20
2023 Q3	$1.15M	Sell	7,708 -62	-0.8%	-$9.1K	1.3%	20
2023 Q2	$1.05M	Sell	7,770 -48	-0.6%	-$7.04K	1.14%	23
2023 Q1	$1.25M	Buy	7,818 +25	+0.3%	+$3.82K	1.5%	15
2022 Q4	$1.26M	Buy	7,793 +147	+2%	+$22.5K	1.53%	13
2022 Q3	$1.03M	Buy	7,646 +57	+0.8%	+$8.18K	1.51%	14
2022 Q2	$1.16M	Sell	7,589 -2,519	-25%	-$385K	1.6%	10
2022 Q1	$1.37M	Hold	10,108	–	–	1.49%	13
2021 Q4	$1.37M	Buy	+10,108	New	+$1.19M	1.53%	13

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

1620 Investment Advisors's ABBV Position: Q2 2026 in Review

1620 Investment Advisors reduced its AbbVie (ABBV) stake by 5.1% in Q2 2026, selling an estimated $83.3K and leaving 7,146 shares worth $1.8M. The position accounts for 1.11% of the portfolio, ranked #16.

1620 Investment Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

1620 Investment Advisors held 7,146 shares of AbbVie worth $1.8M as of Q2 2026.
1620 Investment Advisors sold 387 AbbVie shares in Q2 2026, an estimated $83.3K.
AbbVie made up 1.11% of 1620 Investment Advisors's portfolio in Q2 2026, its #16 holding.
1620 Investment Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.